| Business Summary | | Kensey
Nash
Corporation
designs,
develops,
manufactures
and
processes
proprietary
biomaterials
products
for
the
orthopedics,
cardiology,
drug/biologics
delivery
and
wound
care
markets.
The
Company
is
also
a
leader
in
cardiovascular
medical
technology,
specifically,
arterial
revascularization
and
puncture
closure
devices.
The
Company
is
in
clinical
trials
with
the
Aegis
Vortex
System,
a
device
designed
to
remove
occlusive
material
from
saphenous
vein
grafts
implanted
during
coronary
bypass
surgeries.
Additionally,
the
Company
was
the
original
designer,
developer,
and
manufacturer
of
the
Angio-Seal,
a
device
designed
to
seal
and
close
femoral
artery
punctures
made
during
diagnostic
and
therapeutic
cardiovascular
catheterizations.
In
September
2000,
the
Company
acquired
THM
Biomedical,
Inc.,
a
company
focused
on
developing
tissue
engineering
devices
for
the
repair
and
replacement
of
musculoskeletal
tissues. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Kensey
Nash
designs,
develops,
manufactures
and
markets,
both
individually
and
in
conjunction
with
third
parties,
medical
devices
for
use
primarily
in
the
cardiovascular
and
orthopedic
markets.
For
the
fiscal
year
ended
6/30/01,
revenues
rose
17%
to
$23.2
million.
Net
income
fell
24%
to
$3.6
million.
Revenues
reflect
growth
in
biomaterials
sales
and
acquisitions.
Net
income
was
offset
by
a
$7.6
million
in-process
research
and
development
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Joseph Kaufmann, 48 CEO,
Pres, Sec., | $209K | Wendy DiCicco, 61 CFO | 99K | Douglas Evans, 36 COO,
Assistant Sec., | 169K | John Nash, 65 VP
of New Technologies | 181K | Julie Broderick, 61 VP
of Clinical and Regulatory Affairs | 113K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|